Dr. Jane Zhang has over 30 years of experience in regulatory affairs and drug research and development. She joined EdiGene in 2021 and is currently Sr. Director, Regulatory Affairs (China). 

Dr. Jane Zhang has over 16 years of experience in regulatory affairs with MNCs and biotech，including Novartis, ICON Plc., Roche, Baxter, Daiichi Sankyo and Clover Biopharma, where she was responsible for regulatory affairs and strategy covering drugs’ full life cycle. Her experience was on various therapeutics areas, including cancer, transplantation immunology, hematology, cardiovascular, anti-infection, respiratory as well as vaccine. Before that, Jane worked at the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) as reviewer for evaluation of drug candidates for oncology, Neurological diseases, digestive disease, cardiovascular disease, infectious diseases, etc. Jane also has rich experience in innovative drug research and development. She has published a number of papers and was certificated of Senior Engineer for Biopharma.